All In Biotech

Drug Trial Radar · NCT02531438

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia

Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 774 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

774

Actual

Start

Nov 2015

Primary completion

Feb 5, 2017

Study completion Mar 10, 2017

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Aug 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Conditions

  • Bacterial Pneumonia
  • Community-Acquired Infections

Interventions

  • OmadacyclineDrug

    Injection for IV; Oral tablets

  • MoxifloxacinDrug

    IV solution; Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Early Clinical ResponseTime frame: Screening; 72 to 120 hours after the first dose of test article

Locations

140 sites in 25 countries. Site status is shown where the registry gives one.

  • Site 514

    Birmingham, Alabama

  • Site 501

    Mobile, Alabama

  • Site 508

    Laguna Hills, California

  • Site 505

    Ventura, California

  • Site 513

    Stamford, Connecticut

  • Site 511

    Zachary, Louisiana

  • Site 503

    Detroit, Michigan

  • Site 520

    Saint Paul, Minnesota

  • Site 512

    St Louis, Missouri

  • Site 506

    Buffalo, New York

  • Site 509

    Dayton, Ohio

  • Site 516

    Huntington, West Virginia

  • Site 220

    Liège, Belgium

  • Site 276

    Belo Horizonte, Minas Gerais, Brazil

  • Site 277

    Passo Fundo, Rio Grande do Sul, Brazil

  • Site 274

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site 279

    São José do Rio Preto, São Paulo, Brazil

  • Site 305

    Kyustendil, Bulgaria

  • Site 303

    Pernik, Bulgaria

  • Site 304

    Plovdiv, Bulgaria

  • Site 306

    Sliven, Bulgaria

  • Site 301

    Sofia, Bulgaria

  • Site 302

    Sofia, Bulgaria

  • Site 307

    Sofia, Bulgaria

  • Site 250

    Požega, Croatia

  • Site 205

    Slavonski Brod, Croatia

  • Site 212

    Zadar, Croatia

  • Site 201

    Zagreb, Croatia

  • Site 202

    Zagreb, Croatia

  • Site 203

    Zagreb, Croatia

  • Site 251

    Zagreb, Croatia

  • Site 405

    Zagreb, Croatia

  • Site 412

    Kyjov, Czechia

  • Site 410

    Prague, Czechia

  • Site 411

    Prague, Czechia

  • Site 414

    Třebíč, Czechia

  • Site 390

    Tbilisi, Georgia

  • Site 391

    Tbilisi, Georgia

  • Site 392

    Tbilisi, Georgia

  • Site 393

    Tbilisi, Georgia

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.